全球首个AI医学影像大模型技术与商业化先行者！年收增速超30%

Core Insights - The article highlights the rapid growth and potential of the AI medical imaging sector, with Deshi Biotechnology Co., Ltd. (Deshi Bio) leading the field and preparing for an IPO in Hong Kong through the 18A process [1][11]. Company Overview - Deshi Bio was founded by Dr. Song Ning, who has a multidisciplinary background in computer science, life sciences, and clinical medicine, and has received significant recognition from the primary capital market [1][2]. - The company has undergone five rounds of financing since its establishment in 2016, achieving a valuation of 2.56 billion RMB [1][3]. Ownership Structure - Dr. Song holds over 50% of the voting rights, with a direct shareholding of 30.04% and control through various investment platforms [3][4]. - The company has seen dilution of shares due to external investments, but Dr. Song has strategically repurchased shares to maintain control [2][4]. Strategic Focus - Deshi Bio is divesting from low-margin businesses to concentrate on its core AI medical imaging operations, reflecting a commitment to high-value areas [5]. - The company has developed a comprehensive ecosystem for AI medical imaging, including innovative products like AutoVision® and MetaSight®, which have received multiple international certifications [7][8]. Market Potential - The AI medical imaging market in China is projected to grow at a compound annual growth rate (CAGR) of 60.2%, with the market size expected to reach 40.1 billion RMB by 2030 [6][7]. - Deshi Bio has achieved a 30.6% market share in the chromosome analysis system sector, positioning itself as a leading player in the industry [8]. Financial Performance - In 2024, Deshi Bio reported revenues of approximately 70.35 million RMB, a year-on-year increase of 33.1%, driven by the growth of its cloud service offerings [9][10]. - The company has improved its gross profit margin to 65.5%, indicating strong profitability potential within the medical device sector [9]. Future Plans - The funds raised from the IPO will be allocated to market promotion and further development of AI products, aiming to transition from an "AI tool provider" to a "full-modal medical AI infrastructure architect" [11][12].